217 related articles for article (PubMed ID: 29948642)
1. Metabolic Imaging Phenotype Using Radiomics of [
Chen SW; Shen WC; Chen WT; Hsieh TC; Yen KY; Chang JG; Kao CH
Mol Imaging Biol; 2019 Feb; 21(1):183-190. PubMed ID: 29948642
[TBL] [Abstract][Full Text] [Related]
2. Genetic Alterations in Colorectal Cancer Have Different Patterns on 18F-FDG PET/CT.
Chen SW; Lin CY; Ho CM; Chang YS; Yang SF; Kao CH; Chang JG
Clin Nucl Med; 2015 Aug; 40(8):621-6. PubMed ID: 26018692
[TBL] [Abstract][Full Text] [Related]
3. Imaging phenotype using
Lim CH; Cho YS; Choi JY; Lee KH; Lee JK; Min JH; Hyun SH
Eur J Nucl Med Mol Imaging; 2020 Aug; 47(9):2113-2122. PubMed ID: 32002592
[TBL] [Abstract][Full Text] [Related]
4. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer.
Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y
J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109
[TBL] [Abstract][Full Text] [Related]
5. Correlation between PET/CT parameters and KRAS expression in colorectal cancer.
Chen SW; Chiang HC; Chen WT; Hsieh TC; Yen KY; Chiang SF; Kao CH
Clin Nucl Med; 2014 Aug; 39(8):685-9. PubMed ID: 24978328
[TBL] [Abstract][Full Text] [Related]
6. Impact of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer.
Sasaki K; Kawasaki H; Sato M; Koyama K; Yoshimi F; Nagai H
Dig Surg; 2017; 34(1):60-67. PubMed ID: 27454870
[TBL] [Abstract][Full Text] [Related]
7. Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients.
Krikelis D; Skoura E; Kotoula V; Rondogianni P; Pianou N; Samartzis A; Xanthakis I; Fountzilas G; Datseris IE
Anticancer Res; 2014 May; 34(5):2571-9. PubMed ID: 24778079
[TBL] [Abstract][Full Text] [Related]
8.
Tsujikawa T; Rahman T; Yamamoto M; Yamada S; Tsuyoshi H; Kiyono Y; Kimura H; Yoshida Y; Okazawa H
Ann Nucl Med; 2017 Nov; 31(9):678-685. PubMed ID: 28815452
[TBL] [Abstract][Full Text] [Related]
9. The value of
Oner AO; Budak ES; Yıldırım S; Aydın F; Sezer C
Hell J Nucl Med; 2017; 20(2):160-165. PubMed ID: 28697193
[TBL] [Abstract][Full Text] [Related]
10. Elevated tumor-to-liver uptake ratio (TLR) from
Huang J; Huang L; Zhou J; Duan Y; Zhang Z; Wang X; Huang P; Tan S; Hu P; Wang J; Huang M
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1958-1968. PubMed ID: 28812134
[TBL] [Abstract][Full Text] [Related]
11. Dual-Energy Computed Tomography-Based Iodine Quantitation for Response Evaluation of Lung Cancers to Chemoradiotherapy/Radiotherapy: A Comparison With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Based Positron Emission Tomography/Computed Tomography Response Evaluation Criterion in Solid Tumors.
Ren Y; Jiao Y; Ge W; Zhang L; Hua Y; Li C; Zhai W; Tang X; He W; Fang M; Zheng X
J Comput Assist Tomogr; 2018; 42(4):614-622. PubMed ID: 29613988
[TBL] [Abstract][Full Text] [Related]
12. 4'-[methyl-
Fukuda Y; Yamamoto Y; Mitamura K; Ishikawa R; Asano E; Toyohara J; Norikane T; Nishiyama Y
Ann Nucl Med; 2019 Nov; 33(11):822-827. PubMed ID: 31401773
[TBL] [Abstract][Full Text] [Related]
13. (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status.
Lovinfosse P; Koopmansch B; Lambert F; Jodogne S; Kustermans G; Hatt M; Visvikis D; Seidel L; Polus M; Albert A; Delvenne P; Hustinx R
Br J Radiol; 2016 Jul; 89(1063):20160212. PubMed ID: 27146067
[TBL] [Abstract][Full Text] [Related]
14. Relationship between KRAS mutations and dual time point
Mao W; Zhou J; Zhang H; Qiu L; Tan H; Hu Y; Shi H
Abdom Radiol (NY); 2019 Jun; 44(6):2059-2066. PubMed ID: 30143816
[TBL] [Abstract][Full Text] [Related]
15. The significant value of predicting prognosis in patients with colorectal cancer using
Xu J; Li Y; Hu S; Lu L; Gao Z; Yuan H
Ann Nucl Med; 2019 Jan; 33(1):32-38. PubMed ID: 30218280
[TBL] [Abstract][Full Text] [Related]
16. FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer.
Lovinfosse P; Polus M; Van Daele D; Martinive P; Daenen F; Hatt M; Visvikis D; Koopmansch B; Lambert F; Coimbra C; Seidel L; Albert A; Delvenne P; Hustinx R
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):365-375. PubMed ID: 29046927
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of F-18 FDG PET/CT for prediction of KRAS mutation in colorectal cancer patients: a systematic review and meta-analysis.
Kim SJ; Pak K; Kim K
Abdom Radiol (NY); 2019 May; 44(5):1703-1711. PubMed ID: 30603881
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of
Grut H; Dueland S; Line PD; Revheim ME
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):218-225. PubMed ID: 29026950
[TBL] [Abstract][Full Text] [Related]
20. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS.
Iwamoto M; Kawada K; Nakamoto Y; Itatani Y; Inamoto S; Toda K; Kimura H; Sasazuki T; Shirasawa S; Okuyama H; Inoue M; Hasegawa S; Togashi K; Sakai Y
J Nucl Med; 2014 Dec; 55(12):2038-44. PubMed ID: 25453050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
